Business
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellit...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven\n\n\n\n\n\n\n Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell’s pivotal Phase 3 study\n \n\n\n\n\n\n BriaCell’s Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center\n \n\n\n\n\n PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of two key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as\n \n NCT06072612\n \n ): Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven. Each has 15 satellite locations. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as H1-2026.\n \n\n BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT™, plus immune check point inhibitor (CPI) versus physician’s choice in\n \n a\n \n dvanced metastatic\n \n b\n \n reast\n \n c\n \n ancer (Bria-ABC).\n \n\n “Clinical investigator interest in our Phase 3 study has exceeded our expectations which has significantly expanded patient access to our treatment,” stated Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. “This strong engagement reflects both the urgent unmet need in metastatic breast cancer and the dedication of our clinical partners.”\n \n\n Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combina...